<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954601</url>
  </required_header>
  <id_info>
    <org_study_id>ORA-D-012</org_study_id>
    <nct_id>NCT02954601</nct_id>
  </id_info>
  <brief_title>A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase 2a, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Way Crossover Study to Compare Safety, Efficacy, and Pharmacodynamics of Single and Multiple Doses of ORMD-0801 in Adult Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oramed, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Integrium</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oramed, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a four-way crossover (non-parallel) study with each subject receiving three of the
      four arms. The study will enroll approximately 30 adult subjects with T2DM from age 20 to 75
      inclusive.

      Following a 7-10 day Screening period, eligible subjects will enter a 3-day single-blind
      placebo run-in. On Day 4, each subject will be randomized to a treatment sequence that will
      include three treatment assignments for each of three treatment Periods according to the
      randomization scheme.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following the screening, eligible subjects entered a 3-day, single-blind placebo run-in. On
      Day 4, each subject was randomized to a treatment sequence that included three treatment
      assignments for each of three treatment Periods according to the randomization scheme.

      Pre-assignment Details The number of participants receiving each Intervention, in each
      Period, is reported.

      Subjects received the randomized treatment from Day 4 through Day 8. There was a 24-hour
      single-blind placebo washout on Day 9. Each subject received placebo for one of the three
      treatment periods. Each subject also received 1 of the 3 active doses randomly in each of the
      two other treatment periods respectively. The dosing order is random.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">March 15, 2017</completion_date>
  <primary_completion_date type="Actual">February 24, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Glucose Levels Between Pre-treatment and End of Treatment as Measured by 24-hour Continuous Glucose Monitoring (CGM)</measure>
    <time_frame>Day 3 (run-in) and Day 8 (Day 5 of Active treatment)</time_frame>
    <description>Measure the change in Glucose (mg/dL) by 24 hour CGM between Day3 and Day8 (Change in mg/dL between run-in and Day 5 of Active treatment)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calculate the C-peptide Ratio for Single and Multiple Doses of ORMD-0801 vs Placebo.</measure>
    <time_frame>Day 3 and Day 8</time_frame>
    <description>For each dose, calculate the ratio of the C-Peptide measurement area-under-the-curve (ng-hr/mL) Day 8 to the C-peptide measurement area-under-the-curve (ng-hr/mL) Day 3. This ratio is called the C-peptide Ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number Hypoglycemic Events for Single and Multiple Doses of ORMD-0801 vs Placebo</measure>
    <time_frame>Day 3 through Day 8 of treatment</time_frame>
    <description>The number of safety parameter hypoglycemic events for single and multiple doses of ORMD-0801 vs placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculate the Difference Between Values of Pre-treatment and End-of-treatment Mean Daytime CGM Glucose</measure>
    <time_frame>Day 3 and Day 8 (two timepoints)</time_frame>
    <description>Calculate the difference between pre-treatment (Day 3) and end of treatment (Day 8) mean daytime CGM glucose for single and multiple doses of ORMD-0801 vs placebo.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo (fish oil)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose 1 ORMD-0801 (qd)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose 2 ORMD-0801 (bid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose 3 ORMD-0801 (tid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORMD-0801 (qd)</intervention_name>
    <description>Dose 1 = ORMD-0801 (qd)</description>
    <arm_group_label>Dose1</arm_group_label>
    <other_name>Oral Insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORMD-0801 (bid)</intervention_name>
    <description>Dose 2 = ORMD-0801 (bid)</description>
    <arm_group_label>Dose2</arm_group_label>
    <other_name>Oral Insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORMD-0801 (tid)</intervention_name>
    <description>Dose 3 = ORMD-0801 (tid)</description>
    <arm_group_label>Dose 3</arm_group_label>
    <other_name>Oral Insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>fish oil placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>fish oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects, age 20 to 75 years, inclusive with type 2 diabetes mellitus.

          -  At Visit 2/Period 1/Day 1, subjects will have been treated for their diabetes by
             metformin (≥1000 mg/day; any type and regimen), metformin and a DPP-4 inhibitor (
             Dipeptidyl-Peptidase)-4), metformin and an SGLT-2 (Sodium-glucose co-transporter 2)
             inhibitor, metformin and TZD (Thiazolidinediones), or metformin and sulfonylurea.
             Subjects will have been on a stable regimen of metformin (defined as the same
             metformin dose and type) and other treatments for at least 8 weeks prior to Visit
             2/Period 1/Day 1.

          -  Body Mass Index (BMI) between 25 and 40 kg/m2, inclusive, at Screening.

          -  Hemoglobin A1c (HbA1c) between ≥7.5 and ≤10.5% at Screening.

          -  Fasting serum glucose greater than or equal to 126 mg/dL at Screening.

          -  Females of childbearing potential must have a negative serum pregnancy test result at
             Screening and a negative urine pregnancy test at Visit 2/Day 1 for all study Periods.

          -  Females who are not of childbearing potential are defined as:

             i. Postmenopausal (defined as at least 12 months with no menses in women ≥45 years of
             age) ii. Has had a hysterectomy and/or bilateral oophorectomy, bilateral
             salpingectomy, or bilateral tubal ligation/occlusion at least 6 weeks prior to
             screening; OR iii. Has a congenital or acquired condition that prevents childbearing.

          -  Females of childbearing potential agree to avoid becoming pregnant while receiving
             study treatment and for 14 days after the last dose of study treatment by complying
             with one of the following:

             i. practice abstinence† from heterosexual activity OR ii. Use (or have her partner
             use) acceptable contraception during heterosexual activity.

        Exclusion Criteria:

          -  Usage of anti-diabetic agents other than metformin, sulfonylurea, SGLT-2 inhibitors,
             TZD, or DPP-4 inhibitors within 6 weeks prior to Visit 2/Period 1/Day 1.

          -  Presence of any clinically significant endocrine disease according to the Investigator
             (euthyroid subjects on replacement therapy will be included if the dosage of thyroxine
             is stable for at least six weeks prior to Screening).

          -  Clinical diagnosis of type 1 diabetes.

          -  Fasting serum glucose &gt;300 mg/dL at Screening; a single repeat test is allowable.

          -  Evidence of unawareness of hypoglycemia, a documented plasma glucose ≤50 mg/dL in the
             absence of symptoms of hypoglycemia at Screening.

          -  Presence of any clinically significant condition (in the opinion of the Investigator)
             that might interfere with the evaluation of study medication, such as significant
             renal, hepatic, gastrointestinal (GI), cardiovascular (CV), immune disease, blood
             dyscrasias or any disorders causing hemolysis or unstable red blood cells, or
             clinically important hematological disorders (i.e. aplastic anemia, myeloproliferative
             or myelodysplastic syndromes, thrombocytopenia) at Screening.

          -  Presence or history of cancer within the past 5 years of Screening, with the exception
             of adequately-treated localized basal cell skin cancer or in situ uterine cervical
             cancer.

               1. A subject with a history of malignancy &gt;5 years prior to Screening should have no
                  evidence of residual or recurrent disease.

               2. A subject with a history of melanoma, leukemia, lymphoma, or renal carcinoma is
                  excluded.

          -  Laboratory abnormalities at Screening including:

               1. C-peptide &lt; 1.0 ng/mL;

               2. Positive pregnancy test in females of childbearing potential (at Screening and
                  Visit 2/Periods 1-3/Day 1);

               3. Abnormal serum thyrotropin (TSH) levels below the lower limit of normal or &gt;1.5X
                  (1.5 times) the upper limit of normal

               4. Elevated liver enzymes (alanine transaminase (ALT), alanine aminotransferase
                  (AST), alkaline phosphatase) &gt;2X the upper limit of normal.

               5. Very high triglyceride levels (&gt;600 mg/dL); a single repeat test is allowable.

               6. Any relevant abnormality that would interfere with the efficacy or the safety
                  assessments during study treatment administration.

          -  Positive history of active liver disease (other than non-alcoholic hepatic steatosis),
             including chronic hepatitis B or C, primary biliary cirrhosis, or active symptomatic
             gallbladder disease.

          -  Positive history of HIV.

          -  Use of the following medications:

               1. History of use of insulin for more than 1 week within 6 months prior to and none
                  within 6 weeks prior to Visit 2/Period 1/Day 1.

               2. History of use of aprotinin at any time prior to Screening (e.g., Trasylol, any
                  type or dose).

               3. Administration of thyroid preparations or thyroxine (except in subjects on stable
                  replacement therapy) within 6 weeks prior to Screening.

               4. Administration of systemic long-acting corticosteroids within two months or
                  prolonged use (more than one week) of other systemic corticosteroids or inhaled
                  corticosteroids (if daily dosage is &gt; 1,000 μg equivalent beclomethasone) within
                  30 days prior to Screening. Intra-articular and/or topical corticosteroids are
                  not considered systemic.

               5. Use of medications known to modify glucose metabolism or to decrease the ability
                  to recover from hypoglycemia such as oral, parenteral, and inhaled steroids (as
                  discussed above), and immunosuppressive or immunomodulating agents.

          -  Subject is on a weight loss program and is not in the maintenance phase, or subject
             has started weight loss medication (e.g., orlistat or liraglutide), within 8 weeks
             prior to Screening. Subjects who have had bariatric surgery are also excluded.

          -  Subject is pregnant or breast-feeding.

          -  Subject has a Screening systolic blood pressure ≥165 mmHg or diastolic blood pressure
             ≥100 mmHg. Subjects will be allowed to take a BP rescue medication.

          -  Subject is a user of recreational or illicit drugs or has had a recent history (within
             1 year of Screening) of drug or alcohol abuse or dependence. (Note: Alcohol abuse
             includes heavy alcohol intake as defined by &gt;3 drinks per day or &gt;14 drinks per week,
             or binge drinking) at Screening.

          -  Any clinically significant ECG abnormality at Screening or cardiovascular disease.
             Clinically significant cardiovascular disease will include:

               1. History of stroke, transient ischemic attack, or myocardial infarction within 6
                  months prior to Screening,

               2. History of or currently have New York Heart Associate Class II-IV heart failure
                  prior to Screening, or

          -  One or more contraindications to metformin.

          -  At the Principal Investigator's discretion, any condition or other factor that is
             deemed unsuitable for subject enrollment into the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel M Neutel, M. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orange County Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>October 13, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <results_first_submitted>February 15, 2018</results_first_submitted>
  <results_first_submitted_qc>July 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2018</results_first_posted>
  <last_update_submitted>July 11, 2018</last_update_submitted>
  <last_update_submitted_qc>July 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral Insulin</keyword>
  <keyword>DM T2 (Diabetes Mellitus Type 2)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 23, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT02954601/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT02954601/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Following the screening, eligible subjects entered a 3-day, single-blind placebo run-in. On Day 4, each subject was randomized to a treatment sequence for each of three treatment periods, each period was either placebo or 1 of the 3 treatments). All subjects received placebo and only 2 of the 3 treatments.</recruitment_details>
      <pre_assignment_details>The number of participants receiving each intervention, in each Period, is reported. In each treatment period, each subject received randomly either placebo, qd, bid, or tid for each of 3 treatment periods. Subjects received the randomized treatment from Day 4 through Day 8. There was a 24-hour single-blind placebo washout on Day 9.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo (fish oil) Placebo: fish oil placebo</description>
        </group>
        <group group_id="P2">
          <title>Dose1</title>
          <description>Dose 1 = ORMD-0801 qid</description>
        </group>
        <group group_id="P3">
          <title>Dose2</title>
          <description>Dose 2 = ORMD-0801 bid</description>
        </group>
        <group group_id="P4">
          <title>Dose 3</title>
          <description>Dose 3 = ORMD-0801 tid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (Five Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention (Five Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention (Five Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT Population</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo (fish oil)</description>
        </group>
        <group group_id="B2">
          <title>ORMD-0801 qd</title>
          <description>Oral Insulin once per day</description>
        </group>
        <group group_id="B3">
          <title>ORMD-0801 Bid</title>
          <description>Oral Insulin twice per day</description>
        </group>
        <group group_id="B4">
          <title>ORMD-0801 Tid</title>
          <description>Oral Insulin three times per day</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.27" spread="7.00"/>
                    <measurement group_id="B2" value="57.17" spread="11.37"/>
                    <measurement group_id="B3" value="59.5" spread="7.03"/>
                    <measurement group_id="B4" value="58.71" spread="7.54"/>
                    <measurement group_id="B5" value="57.72" spread="7.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Child-Bearing Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Not Applicable (Male)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Of Childbearing Potential</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Post Hysterectomy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Surgically Sterilized</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>At least 1 year Post-Menopausal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol History</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Never</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Current</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Former</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tobacco History</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Never</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Current</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Former</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Caffiene History</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Never</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Current</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Former</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Glucose Levels Between Pre-treatment and End of Treatment as Measured by 24-hour Continuous Glucose Monitoring (CGM)</title>
        <description>Measure the change in Glucose (mg/dL) by 24 hour CGM between Day3 and Day8 (Change in mg/dL between run-in and Day 5 of Active treatment)</description>
        <time_frame>Day 3 (run-in) and Day 8 (Day 5 of Active treatment)</time_frame>
        <population>Intend to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Fish Oil placebo</description>
          </group>
          <group group_id="O2">
            <title>Dose 1</title>
            <description>ORMD-0801 qid</description>
          </group>
          <group group_id="O3">
            <title>Dose 2</title>
            <description>ORMD-0801 bid</description>
          </group>
          <group group_id="O4">
            <title>Dose 3</title>
            <description>ORMD-0801 tid</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glucose Levels Between Pre-treatment and End of Treatment as Measured by 24-hour Continuous Glucose Monitoring (CGM)</title>
          <description>Measure the change in Glucose (mg/dL) by 24 hour CGM between Day3 and Day8 (Change in mg/dL between run-in and Day 5 of Active treatment)</description>
          <population>Intend to Treat Population</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.94" spread="4.418"/>
                    <measurement group_id="O2" value="-10.00" spread="7.236"/>
                    <measurement group_id="O3" value="-1.21" spread="7.397"/>
                    <measurement group_id="O4" value="-11.42" spread="8.451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Values obtained using a Mixed Model Repeated Measures Analysis of Variance with an unstructured covariance matrix. Treatment, Period and Baseline value (for change and percent change) are factors in the model with repeated values for a subject.</non_inferiority_desc>
            <p_value>0.1311</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Calculate the C-peptide Ratio for Single and Multiple Doses of ORMD-0801 vs Placebo.</title>
        <description>For each dose, calculate the ratio of the C-Peptide measurement area-under-the-curve (ng-hr/mL) Day 8 to the C-peptide measurement area-under-the-curve (ng-hr/mL) Day 3. This ratio is called the C-peptide Ratio.</description>
        <time_frame>Day 3 and Day 8</time_frame>
        <population>Intend to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Fish Oil placebo</description>
          </group>
          <group group_id="O2">
            <title>Dose 1</title>
            <description>ORMD-0801 qid</description>
          </group>
          <group group_id="O3">
            <title>Dose 2</title>
            <description>ORMD-0801 bid</description>
          </group>
          <group group_id="O4">
            <title>Dose 3</title>
            <description>ORMD-0801 tid</description>
          </group>
        </group_list>
        <measure>
          <title>Calculate the C-peptide Ratio for Single and Multiple Doses of ORMD-0801 vs Placebo.</title>
          <description>For each dose, calculate the ratio of the C-Peptide measurement area-under-the-curve (ng-hr/mL) Day 8 to the C-peptide measurement area-under-the-curve (ng-hr/mL) Day 3. This ratio is called the C-peptide Ratio.</description>
          <population>Intend to Treat (ITT)</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="0.034"/>
                    <measurement group_id="O2" value="1.01" spread="0.056"/>
                    <measurement group_id="O3" value="1.03" spread="0.047"/>
                    <measurement group_id="O4" value="0.93" spread="0.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number Hypoglycemic Events for Single and Multiple Doses of ORMD-0801 vs Placebo</title>
        <description>The number of safety parameter hypoglycemic events for single and multiple doses of ORMD-0801 vs placebo.</description>
        <time_frame>Day 3 through Day 8 of treatment</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Fish Oil placebo</description>
          </group>
          <group group_id="O2">
            <title>Dose 1</title>
            <description>ORMD-0801 qid</description>
          </group>
          <group group_id="O3">
            <title>Dose 2</title>
            <description>ORMD-0801 bid</description>
          </group>
          <group group_id="O4">
            <title>Dose 3</title>
            <description>ORMD-0801 tid</description>
          </group>
        </group_list>
        <measure>
          <title>The Number Hypoglycemic Events for Single and Multiple Doses of ORMD-0801 vs Placebo</title>
          <description>The number of safety parameter hypoglycemic events for single and multiple doses of ORMD-0801 vs placebo.</description>
          <population>Safety population</population>
          <units>number of hypoglycemic events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Calculate the Difference Between Values of Pre-treatment and End-of-treatment Mean Daytime CGM Glucose</title>
        <description>Calculate the difference between pre-treatment (Day 3) and end of treatment (Day 8) mean daytime CGM glucose for single and multiple doses of ORMD-0801 vs placebo.</description>
        <time_frame>Day 3 and Day 8 (two timepoints)</time_frame>
        <population>Intend to Treat mean values reported for Doses 1, 2, and 3 are placebo-adjusted doses (Active dose mean minus placebo dose mean)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Fish Oil placebo</description>
          </group>
          <group group_id="O2">
            <title>Dose 1</title>
            <description>ORMD-0801 qid</description>
          </group>
          <group group_id="O3">
            <title>Dose 2</title>
            <description>ORMD-0801 bid</description>
          </group>
          <group group_id="O4">
            <title>Dose 3</title>
            <description>ORMD-0801 tid</description>
          </group>
        </group_list>
        <measure>
          <title>Calculate the Difference Between Values of Pre-treatment and End-of-treatment Mean Daytime CGM Glucose</title>
          <description>Calculate the difference between pre-treatment (Day 3) and end of treatment (Day 8) mean daytime CGM glucose for single and multiple doses of ORMD-0801 vs placebo.</description>
          <population>Intend to Treat mean values reported for Doses 1, 2, and 3 are placebo-adjusted doses (Active dose mean minus placebo dose mean)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.11" spread="5.080"/>
                    <measurement group_id="O2" value="-13.96" spread="7.775"/>
                    <measurement group_id="O3" value="1.13" spread="7.772"/>
                    <measurement group_id="O4" value="-16.78" spread="8.613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Values obtained using a Mixed Model Repeated Measures Analysis of Variance with an unstructured covariance matrix. Treatment period and Baseline value (for change and percent change) are factors in the model with repeated values for subject.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3061</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>One Year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo (fish oil) Placebo: fish oil placebo</description>
        </group>
        <group group_id="E2">
          <title>Dose 1</title>
          <description>Dose 1 = ORMD-0801 qid</description>
        </group>
        <group group_id="E3">
          <title>Dose 2</title>
          <description>Dose 2 = ORMD-0801 bid</description>
        </group>
        <group group_id="E4">
          <title>Dose 3</title>
          <description>Dose 3 = ORMD-0801 tid</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MeDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <description>Number of Hypoglycemic events during treatment period</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Metabolism and Nutrional Disorders</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muskuloskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous System Disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Scientific Officer</name_or_title>
      <organization>Oramed</organization>
      <phone>+972-2-566-0001</phone>
      <email>miriam@oramed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

